ASTRAZENECA PHARMA INDIA : CDSCO APPROVES ENHERTU FOR ADDITIONAL BREAST CANCER INDICATION 🏥💊

• 🇮🇳 AstraZeneca Pharma India receives CDSCO approval to import and market Enhertu (Trastuzumab Deruxtecan) 100 mg/5 mL • 🎯 Approval granted for an additional indication in HER2-positive metastatic or unresectable breast cancer • 👩‍⚕️ Enhertu, in combination with Pertuzumab, can now be used as a first-line treatment for eligible adult patients • 📈 Expands the approved usage of AstraZeneca's oncology therapy portfolio in India • 🔬 Enhertu is a targeted HER2-directed antibody-drug conjugate used in advanced breast cancer treatment • ✅ Marketing of the additional indication subject to applicable statutory approvals 🟢 Impact: Positive (Strengthens AstraZeneca's oncology franchise in India, expands addressable patient population and supports future growth from innovative cancer therapies.)

ASTRAZENECA PHARMA IND LT

← Back to feed